Fulgent Genetics (FLGT) Stock Price & Analysis
FLGT Stock Chart & Stats
- Day’s Range
- MXN 376.21 - MXN 396.00
- 52-Week Range
- MXN 243.00 - MXN 545.99
- Previous Close
- MXN 396.81
- Volume
- 2,500
- Average Volume (3M)
- 0
- Market Cap
- MXN 10.66B
- Enterprise Value
- MXN 321.60M
- Total Cash (Recent Filing)
- MXN 257.03M
- Total Debt (Recent Filing)
- MXN 9.42M
- Price to Earnings (P/E)
- ―
- Beta
- 0.48
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -12.21
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong Liquidity
Extremely low leverage and substantial liquidity give Fulgent flexibility to fund operations, acquisitions, product development, and therapeutic programs without heavy debt pressure. This financial cushion can help the company absorb execution setbacks while working to restore profitability.
Anatomic Pathology Expansion
Rapid growth in Anatomic Pathology and successful integration of Bako and StrataDX broaden Fulgent's diagnostic platform and customer reach. The expanded sales organization and expected acquisition contribution provide a tangible foundation for more diversified, recurring laboratory revenue.
Owned Therapeutic Pipeline
Progress for FID-007 and FID-022 gives Fulgent a potential long-term growth avenue beyond laboratory testing. Ownership of the patented CleanChemo platform may support control over development and commercialization, while upcoming clinical milestones could strengthen strategic value.
Bears Say
Persistent Losses And Cash Burn
Sustained operating losses and renewed cash burn indicate that the current business is not yet self-funding. If negative cash generation continues, liquidity will gradually be consumed and management may have less capacity to invest in growth, acquisitions, or therapeutic development.
Revenue-cycle Transition Uncertainty
A prolonged revenue-cycle transition can depress reported revenue and cash collections even when testing activity continues. Incomplete customizations and uncertain recovery timing make forecasting less reliable, complicate operating decisions, and could prolong pressure on margins and working capital.
Precision Diagnostics And Customer-volume Decline
Weakness in Precision Diagnostics and the loss of volume from a major customer pressure both near-term revenue and business mix. Continued customer insourcing could reduce laboratory utilization and make growth dependent on replacing lost volume or accelerating expansion in other segments.
FLGT FAQ
What was Fulgent Genetics’s price range in the past 12 months?
What is Fulgent Genetics’s market cap?
When is Fulgent Genetics’s upcoming earnings report date?
How were Fulgent Genetics’s earnings last quarter?
Is Fulgent Genetics overvalued?
Does Fulgent Genetics pay dividends?
What is Fulgent Genetics’s EPS estimate?
How many shares outstanding does Fulgent Genetics have?
What happened to Fulgent Genetics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fulgent Genetics?
What is the TipRanks Smart Score and how is it calculated?
Fulgent Genetics Stock Smart Score
Company Description
Fulgent Genetics
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ming Hsieh
- Employees
- 1,315
- Website
- www.fulgentgenetics.com
- Address
- 4978 Santa Anita Avenue, El Monte, CA, 91731, US
Fulgent Genetics (FLGT) Earnings & Revenues
FLGT Company Deck
FLGT Earnings Call
Earnings Call SentimentNeutral
The call presents a mixed picture: meaningful operational and near-term financial headwinds driven by a complex revenue-cycle transition and loss of volume from a large customer led management to reduce full-year revenue guidance and report wider losses. Offsetting these challenges are strong cash reserves, successful integration of recent acquisitions, sequential margin improvement, continued share repurchases, product and AI advancements, and tangible progress in the therapeutic pipeline (FID-007 and FID-022). The issues are material to near-term results, but the company retains financial flexibility and long-term growth drivers.
View all MX:FLGT earnings summariesFLGT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 5 | 5 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 10 | 0 | 2 |